"id","rationale","versionIdentifier","uuid:ID","instanceType"
"StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","6897c978-288a-4b3b-b3f7-64e883a44edc","StudyVersion"
